Introduction
ATP13A2 encodes an 1180-amino-acid protein that localizes to lysosomes and late endosomes (Ramirez et al., 2006) . In addition to human fetal brain, the adult human and mouse brain express the highest levels of ATP13A2, especially in human dopaminergic neurons of the substantia nigra (Ramirez et al., 2006) . Within the large P-type superfamily of ATPase transporters, ATP13A2 belongs to the P-5 subfamily, an emerging class in eukaryotes with largely indeterminate substrate specificities and biological roles (Kühlbrandt, 2004) . P-type ATPases share a similar structure, although their sequences vary even within their four principle domains (phosphorylation domain or Pdomain, the nucleotide-binding domain or N-domain, the actuator domain or A-domain and the membrane domain or M-domain (Kühlbrandt, 2004) .
The ATP13A2 gene maps to the PARK9 locus for susceptibility to Parkinson's disease (PD) and ATP13A2 mutations cause Kufor-Rakeb syndrome (KRS) -a severe, early-onset, autosomal recessive form of PD with dementia (Ramirez et al., 2006) . Initially, Hampshire and colleagues mapped the disease to a locus Chr.1p36 in a Jordanian family (Hampshire et al., 2001 ). In 2006, Ramirez et al. identified a diseasecausing, homozygous mutation in ATP13A2 in affected individuals inconsanguineous Chilean family (Ramirez et al., 2006) . The affected individuals had symptom onset around 9-10 years of age and displayed pyramidal dysfunction, dementia, supranuclear gaze palsy, and were responsive to Levodopa treatment (Ramirez et al., 2006) . Since then, consistent with the recessive inheritance, there have been other cases of KRS patients of various ethnicities harboring either homozygous mutations or compound heterozygous mutations in ATP13A2 (Crosiers et al., 2011; Di Fonzo et al., 2007; Eiberg et al., 2012; Malakouti-Nejad et al., 2014; Ning et al., 2008; Paisán-Ruiz et al., 2010; Schneider et al., 2010) .
The first indication that ATP13A2 mutations could cause another distinct disease was in 2011 when mutant ATP13A2 was identified as the cause of adult-onset neuronal ceroid lipofuscinosis (NCL) in Tibetan terriers (Farias et al., 2011; Wöhlke et al., 2011) . NCL is a lysosomal storage disorder (LSD) that causes accelerated accumulation of lipofuscin, an auto-fluorescent pigment that accumulates in autophagic vacuoles of neuronal cells, which has been linked to neurodegeneration, brain atrophy, and neurological symptoms (Mole and Cotman, 2015) . Dogs with ATP13A2-linked NCL harbor a homozygous, single-base deletion which causes a translation frameshift followed by an aberrant premature stop codon in ATP13A2. The behavioral outcomes of KRS in humans and adult-onset NCL in Tibetan terrier partially overlap -both humans and Tibetan terriers with the disease exhibit loss of learning behavior, cognitive decline, and disorientation. However, Tibetan terriers with NCL lack parkinsonism and pyramidal dysfunction that is reported in human KRS patients, but develop cerebellar ataxia, a feature that is not present in KRS (Farias et al., 2011; Wöhlke et al., 2011) . Subsequently, a homozygous mutation (c.2429T > G) in ATP13A2 was associated with human NCL, termed CLN12, in a kindred from Belgium (Bras et al., 2012) . The affected siblings of the Belgian kindred began displaying difficulty with learning at age 8, pyramidal signs, and peripheral neuropathy as well as signs of parkinsonism and cognitive impairment, both of which are features present in KRS (Tomé et al., 1985) .
Both ATP13A2-linked KRS and NCL are recessive diseases, with the associated mutations being either missense or insertions/deletions within the exons encoding the functional domains of the protein which have been predicted to a cause of loss-of-function of ATP13A2. Some of these mutations lead to lowered protein levels or retention in the ER due to impaired protein stability while others undergo nonsense mediated decay due to production of aberrant transcripts (Covy et al., 2012; Dehay et al., 2012; Estrada-Cuzcano et al., 2017; Matsui et al., 2013; Park et al., 2011; Podhajska et al., 2012; Usenovic et al., 2012b) . Given the recessive nature of ATP13A2-linked disease, only a handful of studies have explored the possibility that heterozygous ATP13A2 mutations may be associated with disease development.
Several groups have identified heterozygous ATP13A2 mutations (c.1597G > A, c.2236G > A, c.3040G > A) in cohorts of juvenile or early-onset PD patients of various ethnicities that show classical PD symptoms but lack some of the key features of KRS such as pyramidal deficits, supranuclear gaze palsy (defining feature of KRS), or cognitive deficits (Chen et al., 2011; Di Fonzo et al., 2007; Djarmati et al., 2009; Lin et al., 2008) . Furthermore, several members from the original Chilean and Italian KRS families harboring a single heterozygous mutation (c.3057delC) have developed PD-associated symptoms such as bradykinesia and mild rigidity and postural instability, with nigrostriatal dysfunction Brüggemann et al., 2010; Crosiers et al., 2011) . Contrarily, some studies have not found an association with ATP13A2 heterozygous mutations and PD risk (Fei et al., 2010; Guo et al., 2008; Mao et al., 2010; Rakovic et al., 2009; Vilariño-Güell et al., 2009 ) generating some debate in the field about the pathogenicity of single heterozygous mutations in ATP13A2. Despite this, no human studies exist on how the complete or partial loss of ATP13A2 neuropathologically alters the brain due to lack of human autopsy tissue.
We and others previously have shown that Atp13a2 homozygous knockout (KO) mice develop sensorimotor deficits and robust lipofuscinosis and gliosis (Kett et al., 2015; Sato et al., 2016; Schultheis et al., 2013) . In the present study, we demonstrate quantitatively that complete loss of Atp13a2 causes lipofuscinosis, microgliosis, and astrocytosis extending throughout the cortex, hippocampus, brainstem, and the cerebellum. In contrast, partial loss of Atp13a2 in the heterozygous Atp13a2 KO mice primarily resulted in widespread astrogliosis in the cortex, hippocampus, and brainstem with only modest lipofuscinosis in one of the regions (cortex). These results indicate that both complete and partial loss of Atp13a2 can impact multiple regions of the brain. Importantly, the glial pathology observed in the context of partial loss of Atp13a2 is largely independent of robust lipofuscinosis. Our study suggests that gliosis may serve as an initial pathological process that confers risk for the subsequent development of neurodegenerative disease in human ATP13A2 heterozygous mutation carriers.
Materials and methods

Animal husbandry
All procedures involving mice were conducted per the National Institutes of Health guide for animal care and approved by the Institutional and Animal Care and Use Committee (IACUC) at University of Florida (UF). The Atp13a2-deficient mice were generated previously through targeted disruption of the murine Atp13a2 gene (Schultheis et al., 2013) . The breeding mice were provided by the investigators from Northern Kentucky University, and the colony was expanded and maintained on C57BL/6 background in house. Genomic DNA was obtained by tail biopsy at 21 days and assessed for the wildtype (WT) or KO alleles by PCR as previously described (Schultheis et al., 2013) (Supplementary Fig. 1A ). We utilized PrimeTime Standard qPCR Assay (Integrated DNA Technologies, Atp13a2 Assay ID: Mm.PT.58.42177856), according to the manufacturer instructions, on a subset of our experimental mice to confirm that Atp13a2 expression was reduced in the forebrain of Atp13a2 heterozygous KO (HET) mice and completely absent in the forebrain of Atp13a2 homozygous KO mice when compared to Atp13a2 WT mice ( Supplementary Fig. 1B ).
Tissue harvest
Brains were isolated from WT, HET, and KO mice at~18 months of age (Supplementary Table 1 ). Briefly, the mice were anesthetized with isoflurane and perfused transcardially with 20 mL of phosphate buffered saline (PBS). The brains were immediately removed and hemisected along the sagittal midline. The left hemisphere was immersionfixed in 4% paraformaldehyde for 24-48 h and then transferred to PBS for storage at 4°C until processed for paraffin embedding. The right hemisphere was snap frozen on dry ice and a subset of the frozen brains were used to extract RNA for qPCR analysis. The spinal column was immersion fixed in 4% paraformaldehyde for 24 h. The spinal cord was extracted from the spinal column, and fixed for another 24 h prior to transferring to PBS. All the tissues were stored in PBS at 4°C until processing. The brains and spinal cords were paraffin embedded and cut into 5 μm thick sagittal, serial sections.
Immunohistochemistry
Prior to immunohistochemical analysis, at least two sagittal brain sections stained with hematoxylin and eosin (H&E) were used to align all brains to approximately 0.84 mm lateral to the midline using the mouse brain atlas (Paxinos and Franklin, 2004) . Aligned sections were deparaffinized in xylene and rehydrated in a descending ethanol gradient. For antigen retrieval, the sections were heated in 200 mL of dH 2 O for 30 min using a pre-heated steamer (HS900, Black and Decker, Shelton, CT, USA). Ubiquitin, GFAP, and Iba1 (mouse α-Ubiquitin, Millipore, 1:55000; rabbit α-GFAP, Biogenex, 1:2500; rabbit α-Iba1, Wako Pure Chemicals, 1:3000) immunolabeling was performed using the DAKO Autostainer per manufacturer's instructions using the DAKO Envision+ System peroxidase kit, with 3,3′-diaminobenzidine (DAB) as the chromogen (DAKO, Carpentaria, CA, USA). Sections were counterstained with hematoxylin, dehydrated and coverslipped with Cytoseal (Thermo Scientific). For α-synuclein immunolabeling, we utilized the SNL4 affinity-purified rabbit polyclonal antibody that targets residues 2-12 of the N-terminus of α-synuclein (Giasson et al., 2000) . Brain sections from mice expressing A53T human α-synuclein were used as a positive control (Giasson et al., 2002) . Briefly, the sections were blocked in 0.1 M Tris/2% fetal bovine serum (FBS), and incubated overnight at 4°C with primary antibody diluted in 0.1 M Tris/2% FBS (SNL4, 1:2000) . Subsequently, sections were incubated in biotinylated anti-rabbit antibody (Vector Labs) for 1 h. The signal was detected with a standard peroxidase ABC system (Vector Labs) with DAB as the chromogen, counterstained with hematoxylin, dehydrated and coverslipped with Cytoseal (Thermo Scientific). All brain sections were scanned with ScanScope (Aperio) and representative images were taken using ImageScope (Aperio).
Histology
Mouse brain and spinal cord sections were deparaffinized, rehydrated, and stained with Luxol fast blue-periodic acid Schiff (LFB-PAS) per standard procedures (Margolis and Pickett, 1956 ). Brain and spinal cord sections stained with LFB-PAS were scanned with ScanScope (Aperio) and representative images were taken using ImageScope (Aperio). To demonstrate autofluorescence, three brain sections from each animal of all three genotypes (each section approximately 20 μm apart) were rehydrated and incubated with 4′,6-diamidino-2-phenylindole (DAPI; 1:2000, Fisher, #EN62248) diluted in PBS for 15 min. The sections were subsequently washed thoroughly with PBS and coverslipped with Fluromount G (Fisher, #OB100-01). Lipofuscin was detected similarly in the spinal cord. Fluorescence images of brain regions (3 sections per animal) and spinal cord segments were obtained using a Keyence BZ-X710 fluorescence microscope from every section.
Quantitative pathological analysis
For the sections stained for GFAP and Iba1, the cortex, hippocampus, brainstem, and cerebellum were outlined on a sagittal brain section of mice from each genotype for quantitative pathological analysis (% burden). Rips, folds, and large blood vessels in the tissue were outlined for subtraction. Quantification of GFAP and Iba1 immunoreactivity was performed using ImageScope software (Aperio). Thresholding parameters for each brain region were optimized by using a known WT and KO animal. Subsequently, the burden was assessed on all samples using those algorithms for each region and immunostain. The WT animals used for WT vs. KO comparison were the same as the animals used in WT vs. HET comparison. Pathological analyses were conducted with the investigator blinded to genotypes.
For quantification of lipofuscin, images were taken from each animal (3 brain sections per animal) of the following brain regions: cortex, CA3 of hippocampus, and brainstem. This resulted in each animal having 3 images for each brain region. Every image from each brain region (3 images per animal) was then analyzed using a custom-written MATLAB algorithm. Briefly, background intensity of each image or region-of-interest was determined via median filtering. Every image was binarized using a threshold value, specific for each brain region, which was determined by multiplying a constant number by the image background. The same constant number was used for every image in control and experimental groups for a given brain region. Binary images were used to count lipofuscin structures and calculate their areas. Total fluorescence intensity was calculated by integrating the optical densities from the original image over the areas obtained from binary image. The analysis resulted in each animal containing three total intensity values for each brain region and these were averaged and plotted.
Statistical analysis
This study addressed two main questions: 1) what regions of the Atp13a2 homozygous KO brains are affected by features of NCL and 2) do Atp13a2 HET mice show features of NCL in the brains when compared to WT mice? To answer the first question, statistical analysis was performed between WT and KO mice for each measure and for the brain region of interest. Given the qualitatively striking difference between WT and KO mice for Purkinje cell pathology, we did not perform quantitative measures of lipofuscin in the cerebellum. To answer the second question, statistical analysis was performed between WT and HET mice (the WT animals were the same animals in both analyses). In both cases, we utilized an unpaired, student's t-test using GraphPad Prism version 6.00 (GraphPad Software) and P < 0.05 was considered to be statistically significant. To determine whether one or more values from the quantitative analysis are significant outliers, we performed Grubbs' analysis using GraphPad Software where the significance level was set at 0.05. Any value that was deemed a significant outlier was removed from the specific cohort it belonged to. The following samples were removed from the GFAP burden analysis: one WT sample from the hippocampus cohort, one HET sample from the cortex cohort, and one KO samples from the cerebellum cohort. The following samples were removed from the Iba1 burden analysis: one WT animal from the cerebellum cohort and one HET samples from the brainstem cohort.
Results
Mice deficient of Atp13a2 were generated previously through targeted disruption of the Atp13a2 gene (Schultheis et al., 2013) . The initial characterization of these Atp13a2 homozygous KO mice revealed modest sensorimotor deficits at 23 months, lack of nigral degeneration, a subtle increase in detergent soluble α-synuclein in the hippocampus detected via immunoblot, and accelerated accumulation of lipofuscin in the cerebellum and hippocampus (Schultheis et al., 2013) . In this current report, we extended those pathological studies and defined the distribution of the lipofuscinosis and gliosis within aged (18-month-old) KO mice in comparison to age-matched WT mice to establish the regions that should be the focus for our WT vs. HET studies.
Lipofuscin is a highly autofluorescent, intraneuronal storage material that normally accumulates with increasing age in animals (Gray and Woulfe, 2005) . Utilizing the autofluorescent property of lipofuscin, we measured the total intensities within the cortex, hippocampus, and brainstem as a measure of lipofuscin in 18-month-old (aged) Atp13a2 WT and KO ( Supplementary Fig. 2 ). The aged WT mice normally contained some degree of lipofuscin in the cortex (Supplementary Fig. 2A ) and hippocampus ( Supplementary Fig. 2D ) reflective of the normal aging process. In contrast, aged KO mice show approximately a 2-fold increase of lipofuscin in the cortex in comparison to WT mice (Supplementary Fig. 2A -C, P < 0.0001) and > 2.5-fold increase in the CA3 of the hippocampus of the KO compared to WT mice ( Supplementary  Fig. 2D -F, P = 0.0003). Lipofuscin in the KO mice resembled the classical moon-like crescents around the nuclei within many of the neurons (Gray and Woulfe, 2005) . In the brainstem, KO mice also show a significantly higher level of autofluorescence (~1.6-fold), indicative of lipofuscin accumulation, compared to WT mice ( Supplementary  Fig. 2G -I, P = 0.0023). In the cerebellum, the WT mice ( Supplementary  Fig. 2J & K) presented with a basal level of autofluorescence consistent with aging; whereas, KO mice show striking autofluorescence, indicative of robust lipofuscin accumulation primarily in the Purkinje cells, lining the cerebellar lobes, and within the molecular layer when compared to the WT mice ( Supplementary Fig. 2L & M) . Lipofuscin storage material stains positive with LFB-PAS and is immunopositive for ubiquitin. Both LFB-PAS and ubiquitin positive inclusions were elevated in the KO mice (data not shown) compared to WT mice, qualitatively mirroring the autofluorescence observed in the various brain regions.
Interestingly, lipofuscin laden cells were qualitatively elevated in the cervical (Supplementary Fig. 3B ), thoracic ( Supplementary Fig. 3F ), and lumbar ( Supplementary Fig. 3J ) spinal cord segments of KO mice compared to the basal level of the autofluorescence in the same regions of WT mice ( Supplementary Fig. 3A , E, & I). In both WT and KO mice, lipofuscin granules were located within the ventral horns in all segments of the spinal cord and were predominantly in the grey matter. Lipofuscin granules in the KO mice were positive for LFB-PAS in the spinal cord ( Supplementary Fig. 3D , H, & L insets), but were absent in the WT spinal cord segments (Supplementary Fig. 3C, G, & K) . Although we did not quantify the abundance of lipofuscin in the spinal cords, a blind investigator (J.L.) was able to distinguish WT from KO sections due to the abundance of LFB-PAS positive inclusions in the KO spinal cords. We further validated the presence of lipofuscinosis in the brain and spinal cord by utilizing Sudan Black (not shown) to extinguish the autofluorescence as well as by performing standard staining of lipofuscin with Sudan Black (not shown).
Since lipofuscinosis is typically accompanied by gliosis in human NCL and in model systems of NCL (Radke et al., 2015) , we determined the presence of astrocytosis and microgliosis in aged WT and KO mice. The relative degree of astrocytosis and microgliosis was determined by quantifying glial fibrillary acidic protein (GFAP) and ionized calciumbinding adapter molecule 1 (Iba1) immunoreactivity (% burden), respectively, within the brain regions that were principally studied for lipofuscinosis. In conjunction with the lipofuscin, GFAP positive astrocytes were both qualitatively and quantitatively elevated in the KO compared to WT mice in the cortex ( Supplementary Fig. 4A -C, P < 0.0001), hippocampus ( Supplementary Fig. 4D -F, P = 0.0035), brainstem ( Supplementary Fig. 4G -I, P = 0.0002), and cerebellum ( Supplementary Fig. 4J -L, P = 0.0086). Within the cerebellum, astrocytosis extended throughout the molecular, Purkinje cell, and granule cell layers as well as the white matter of the KO mice. Similar to the patterns observed for GFAP positive astrocytes, Iba-1 burden was consistently higher in the KO mice compared to the WT mice in the cortex ( Supplementary Fig. 5A -C, P = 0.0004), hippocampus ( Supplementary  Fig. 5D -F, P < 0.0001), brainstem ( Supplementary Fig. 5G -I, P = 0.0001) and cerebellum ( Supplementary Fig. 5J -L, P = 0.0095). In the cerebellum, Iba-1 positive microglia were predominantly localized to the white matter; whereas, the localization of astrocytosis was comparatively widespread and more diffuse.
Since ATP13A2 mutations have been linked to development of Parkinson's disease symptoms Brüggemann et al., 2010; Chen et al., 2011; Crosiers et al., 2011; Di Fonzo et al., 2007; Djarmati et al., 2009; Lin et al., 2008) and we previously found that there was a modest increase of detergent soluble α-synuclein in the hippocampus of the Atp13a2 KO mice versus WT mice (Schultheis et al., 2013) , we sought to determine if α-synuclein pathology was present in the brains of Atp13a2 KO mice. In the current study, we were unable to detect changes in α-synuclein aggregation in any regions of the 18-month-old KO mice versus WT mice via immunohistochemistry (Supplementary Fig. 6A & B ). An A53T α-synuclein transgenic mouse served as a positive control ( Supplementary Fig. 6C ) for these studies given that the transgenic animals progressively develop α-synuclein pathology throughout the mouse neuraxis with prominent pathology observed in the brainstem (Giasson et al., 2002) . The lack of α-synuclein aggregation in the Atp13a2 KO mice is consistent with a report in which changes in α-synuclein were absent from a second Atp13a2 KO mouse model (Kett et al., 2015) .
Given the robust NCL-associated pathology and the lack of robust α-synuclein pathology in the Atp13a2 KO mice, we sought to determine if heterozygous Atp13a2 knockout mice may be at risk for NCL pathology rather than PD associated pathology. To study this, we compared the levels of lipofuscin and glial activation between 18-month-old WT and HET mice in the cortex (Figs. 1 & 2) , hippocampus (Figs. 1 & 2) , brainstem (Fig. 3) and cerebellum (Fig. 4) . Qualitatively, WT mice contained autofluorescent lipofuscin in the cortex consistent with age ( Fig. 1A) while the aged HET mice show a subtle but significant increase in autofluorescent lipofuscin in the cortex (Fig. 1B & M , P = 0.0391). In contrast, the degree of autofluorescent lipofuscin in the CA3 of the hippocampus of WT and HET mice was indistinguishable between the two genotypes ( Fig. 1C & D, N , P = 0.7077). Both cortex and CA3 of the hippocampus of HET mice lacked Luxol-fast blue positive inclusions (Fig. 1E-H ) and contained qualitatively indistinguishable amounts of ubiquitin levels when compared to WT mice (Fig. 1I-L) .
As gliosis is a principle pathology in NCL and is a prominent feature of the Atp13a2 KO mouse neuropathology, we sought to determine if partial loss of Atp13a2 also induced glial changes. Astrocytosis was significantly elevated in the cortex of HET mice compared to WT mice (astrocytosis, Fig. 2A & B, E, P = 0.0178) and as was microgliosis (Fig. 2G & H, K, P = 0.0086). Surprisingly, we also observed heightened astrocytosis in the hippocampus (Fig. 2C & D, F, P = 0.0305) of HET mice in comparison to WT mice despite the absence of significant lipofuscinosis in this region. Similarly, incongruent with levels of lipofuscin, increased microgliosis was observed in the hippocampus of HET mice compared to WT mice (Fig. 2I , J, & L, P = 0.0398).
To determine if there was similar incongruity between lipofuscinosis and gliosis across other brain regions, we also examined levels of autofluorescence and gliosis in the brainstem and cerebellum of Atp13a2 HET mice in comparison to WT mice. Levels of autofluorescence indicative of lipofuscin in the brainstem (Fig. 3A -C, P = 0.4964) and qualitatively in the cerebellum (Fig. 4A & B) were indistinguishable between the WT and HET cohorts. Interestingly, increased astrocytosis was observed in the brainstem of HET mice compared to WT mice (Fig. 3D-F , P = 0.0081), consistent with the incongruity between the lipofuscin and gliosis in the hippocampus of HET versus WT mice. Interestingly, microgliosis was unchanged in the brainstem between WT and HET mice (Fig. 3G-I , P = 0.0827). In the cerebellum, astrocytosis was not significantly higher in the cerebellum of the HET compared to WT mice (Fig. 4C, D , & G, P = 0.1399). Additionally, microgliosis changes were not evident in the cerebellum of HET mice versus WT mice (Fig. 4E, F , & H, P = 0.0809).
Discussion
Homozygous or compound heterozygous loss of function mutations in ATP13A2 (PARK9) have been implicated in three diseases: NCL, HSP, and KRS (Bras et al., 2012; Estrada-Cuzcano et al., 2017; Ramirez et al., 2006) . Additionally, heterozygous loss-of-function mutations in ATP13A2 have been linked to early-onset Parkinson's disease (PD) (Chen et al., 2011; Di Fonzo et al., 2007; Djarmati et al., 2009; Lin et al., 2008) . Despite symptomatic overlap across the ATP13A2-linked diseases, it is unclear how loss-of-function mutations in a single gene can cause three different diseases. In fact, the lack of autopsy tissue has made it difficult to even confirm that these three clinical presentations have three distinct pathological profiles. In attempt to bridge this gap in knowledge, Schultheis et al. developed an Atp13a2 KO mouse model with targeted disruption of the murine gene by targeting exons 12-15, which encode the phosphorylation site that is essential for proper function (Kühlbrandt, 2004; Schultheis et al., 2013) . In our previous report, we identified lipofuscinosis as the primary pathology in the brains of the Atp13a2 KO mice at 18-20 months of age, which is consistent with the association of loss of function ATP13A2 mutations with human NCL.
In the present study, we further characterized this mouse model by quantifying the degree of lipofuscinosis in various regions of the CNS of aged (18 month old) Atp13a2 WT and KO mice as well as the amount of gliosis present in these regions. We found robust lipofuscinosis in the cortex, hippocampus, brainstem, cerebellum, and the spinal cord of the Atp13a2 KO mice. Our data is consistent with pathology that has been reported in two different Atp13a2 KO mouse models (Kett et al., 2015; Sato et al., 2016) . Furthermore, the lipofuscin-laden Purkinje cells outlined the cerebellum of the KO mice is similar to what has been reported in a naturally occurring dog model of NCL linked to ATP13A2 (Farias et al., 2011) . It was not surprising to see the cortex and hippocampus affected by significant lipofuscin pathology because endogenous levels of Atp13a2 in the mouse brain are highest in these two brain regions (Lein et al., 2007) , thus complete loss of Atp13a2 in these regions may render them particularly vulnerable. In contrast, the cerebellum has one of the lowest level of expression of Atp13a2 indicating that extent of lipofuscinosis in the KO mice is not entirely consistent with the regions that normally rely on high levels of Atp13a2 expression. It is still possible that the sequence in which brain regions develop lipofuscinosis may correlate to the regions that rely on high levels of Atp13a2; though, this will require a detailed time course to evaluate. NCL in humans is characterized by both astrocytosis and microgliosis (Radke et al., 2015) . Given this, we immunostained brain sections for GFAP and Iba1 to detect activated astrocytes and microglia, respectively, in the same cohort of aged animals. We observe an overwhelming abundance of activated astrocytes and microglia in KO mouse cortex and hippocampus compared to WT animals. These findings were not exclusive to the cortex and hippocampus, as they were also seen in the brainstem, cerebellum, and midbrain regions (not shown) where the degree of lipofuscinosis was robustly elevated.
Given the linkage of ATP13A2 mutations with KRS, an early onset form of PD, we previously evaluated these Atp13a2 KO mice for phenotypic and pathological manifestations of PD; however, we only found subtle sensorimotor deficits and modest increase in detergent soluble α-synuclein compared to WT mice through western blot analysis (Schultheis et al., 2013) . In the current studies, we performed immunohistochemistry on aged WT and KO brains and did not detect α-synuclein positive inclusions indicating that the loss of Atp13a2 is not sufficient to trigger frank α-synuclein inclusion pathology, at least in these mice. It is possible that IHC failed to detect and validate the solubility changes because we used a different antibody; however, we note that Kett et al. also failed to detect any changes in α-synuclein in a second Atp13a2 KO model (Kett et al., 2015) . In aggregate, these findings fail to support that a simple loss of Atp13a2, in the absence of an additional hit, is sufficient to cause a pathological condition reminiscent to human PD, at least during the life span of these mice. Importantly, our data from the Atp13a2 KO mice fall in stark contrast to (Ypk9) and overexpression of the orthologue reduced α-synuclein inclusions and toxicity (Gitler et al., 2009 ). Additionally, knockdown of the C. elegans ATP13A2 orthologue (W08D2.5) or its interacting proteins increased misfolding of α-synuclein (Gitler et al., 2009; Usenovic et al., 2012a) . Similarly, studies of in vitro model systems indicated that ATP13A2 influences α-synuclein levels, solubility, aggregation and toxicity (Dehay et al., 2012; Usenovic et al., 2012b) . Reduction of ATP13A2 in mammalian cell lines or primary neuronal cultures leads to increased α-synuclein, and concomitant overexpression of α-synuclein increased toxicity (Dehay et al., 2012) . It may be possible that loss of ATP13A2 can influence α-synuclein toxicity when α-synuclein is driving the event; however, Kett and colleagues bred α-synuclein overexpressing transgenic mice onto the Atp13a2 KO background and their data does not support this possibility (Kett et al., 2015) . Recently, Fleming et al. demonstrate that while insoluble α-synuclein levels are relatively low in the ventral midbrain of aged Atp13a2 WT and KO mice, upon treatment of manganese (Mn), α-synuclein levels increase significantly in Atp13a2 KO mice compared to Mn-treated WT mice and saline-treated Atp13a2 KO mice (Fleming et al., 2017) . Others have demonstrated that several cationic substrates of ATP13A2, specifically Zn 2+ , may also play a role in the interaction between the two proteins. Tsunemi et al. found that Zn 2+ toxicity impairs lysosomal protease activity and induces accumulation of monomeric and aggregated α-synuclein, and these effects are magnified by loss of functional ATP13A2 (Tsunemi et al., 2014) . It is possible that human and murine ATP13A2/Atp13a2 differ in cation specificities and this could underlie why murine Atp13a2 does not appear to robustly alter α-synuclein. Alternatively, other proteins may be able to compensate for the loss of Atp13a2 in the mouse compared to the human. The linkage of ATP13A2 with both an LSD and a parkinsonian disorder is reminiscent to the link between parkinsonism and mutations in glucocerebrocidase (GBA). Homozygous mutations in GBA cause the most common LSD termed Gaucher's disease; whereas, individuals carrying a single mutant GBA allele have a significant risk for developing PD (Sidransky et al., 2009 ). Parallel to the GBA-LSD-PD relationship, additional human studies have suggested that ATP13A2 may also play a role in sporadic PD. Several independent reports indicate that carrying only one ATP13A2 mutation can confer increased risk of developing PD (Chen et al., 2011; Di Fonzo et al., 2007; Djarmati et al., 2009; Lin et al., 2008) . Moreover, family members in the Chilean and Italian KRS kindreds have developed PD-associated symptoms and harbor a single heterozygous ATP13A2 mutation Crosiers et al., 2011) . While the penetrance of heterozygous ATP13A2 mutations is debatable, several studies have shown that these mutations do indeed have pathogenic effects in vitro (Park et al., 2017; Podhajska et al., 2012) . Recently, Lubbe et al. show that there is a significant enrichment in ATP13A2 heterozygous variants in LRRK2-G2019S PD patients compared to PD patients without the G2019S mutation and healthy controls (Lubbe et al., 2016) . The precise pathogenic mechanism of these ATP13A2 variants with LRRK2-G2019S is unclear, but this highlights the pleiotropic nature of ATP13A2 mutations and the potential convergence of other PD-related genes with ATP13A2-associated diseases. Although naive Atp13a2 KO mice do not appear to intrinsically model PD, they do model key aspects of NCL. Given the data from the Atp13a2 KO mice, we sought to determine if heterozygous loss of Atp13a2 may be a risk factor for neuropathological changes associated with NCL. We expanded our pathological characterization of the Atp13a2 KO mouse model to define whether the cortex, hippocampus, brainstem, and cerebellum are vulnerable to lipofuscin accumulation in 18-month-old Atp13a2 HET knockout mice and if there is an association with gliosis in the same regions. In the cortex, we observed a modest, yet significant increase in lipofuscin levels in the HET mice compared to WT mice; however, changes in lipofuscinosis were not present in the hippocampus, brainstem, or cerebellum of Atp13a2 HET mice. Astrocytosis and microgliosis were prevalent in the cortex in the Atp13a2 HET mice, consistent with the lipofuscinosis in that region, but unexpectedly, astrocytosis was also significantly elevated in the hippocampus and brainstem. Microgliosis was also elevated in the hippocampus of HET mice compared to WT mice. The cerebellum remained unaffected by any of these readouts in the HET mice. Elevated gliosis in the hippocampus and brainstem of the HET mice without the appearance of significant lipofuscinosis may indicate that gliosis is the initial pathological event in the context of loss of Atp13a2. It has previously been reported that gliosis predates the development of detectable lipofuscinosis in another model of NCL -upregulation of astrocytic markers and microglial activation was observed prior to neurodegeneration in a Cln3 homozygous KO mouse model of juvenile NCL (JNCL) (Pontikis et al., 2004) . Similarly, in two other models of lysosomal storage diseases (LSDs), Sandoff disease and Mucolipidosis IV, early and significant increase in neuroinflammatory markers are present prior to neuronal loss (Grishchuk et al., 2014; Wada et al., 2000) . Given this, gliosis independent of robust lipofuscinosis in the Atp13a2 HET mice may indicate that the brain may be under constant stress attempting to compensate for the partial loss Atp13a2 and this may render cells vulnerable to secondary insults which could elicit further pathology. The partial loss of Atp13a2 could be overwhelming the lysosomal degradation pathway, causing other lysosomal enzymes and/or upstream/downstream pathways to compensate for the loss. The compensation mechanisms could cause alterations in neuronal activity that could potentially create widespread stress, such as gliosis.
The compensation induced stress could be considered to be "chronic" and eventually leading to gliosis, which is why increased gliosis but not lipofuscin is observed. This constant maintenance of a stable environment could result in reactive astrocytes which could occur because they have lost their neuroprotective ability or have started to gain neurotoxic effects. Similarly, the microglia may be overwhelmed due to the stressful environment and may start showing signs of abnormal trophic functions.
Atp13a2 mRNA and Atp13a2 protein are present in mesencephalic astrocytes (Qiao et al., 2016) and the complete or partial depletion of ATP13A2 in these cell types could influence astrocytosis through a mechanism that has not been explored in this context: the NLRP3 inflammosome-mediated pathway. NLRP3 inflammasome promotes caspase-1 mediated maturation of inflammatory cytokines Interleukin 1β (IL-1β) and Interleukin 18 (IL-18) (Jo et al., 2016) . Several mechanisms have been suggested for NLRP3 activation, one of which includes lysosomal destabilization and rupture (Heid et al., 2013; Okada et al., 2014) . Since missense or truncation mutations in ATP13A2 compromise the stability of lysosomes and their integrity (Ramirez et al., 2006) , NLRP3 activation could be induced by the loss of ATP13A2. Indeed, Atp13a2 KO significantly increases lysosomal cathepsin B expression within the astrocytes, which induces inflammasome activation through NLRP3, resulting in astrocytic activation (Qiao et al., 2016) . These findings may implicate ATP13A2 in modulating astrocyte-mediated neuroinflammation through the NLRP3 inflammasome pathway.
Conclusion
Our current studies refine the understanding of the extent to which the Atp13a2 KO mice pathologically resemble the ATP13A2-linked NCL. Indeed, the lipofuscinosis and gliosis of this model are consistent with the role of ATP13A2 in NCL; however, the absence of α-synuclein pathology demonstrates the limited intrinsic ability of this model to fully recapitulate all the features of PD. The most striking finding of the present study is derived from the pathological analysis of the Atp13a2 HET mice in which gliosis is present even in the absence of robust lipofuscinosis. This finding indicates that partial loss of ATP13A2 in humans should not be regarded as benign and suggests that reduced levels of Atp13a2 may render the CNS vulnerable to secondary genetic or environmental insults that elicit disease development. It is conceivable that these secondary "hits" could underlie the apparent pleiotropic effects of ATP13A2 mutations.
Supplementary data to this article can be found online at https:// doi.org/10.1016/j.mcn.2018.05.009.
